Big gains in profits and revenue at Sepracor ( SEPR) weren't enough for investors, as they punished the drugmaker's shares on Wednesday.

Although Sepracor beat Wall Street's expectations for the fourth quarter, its stock dropped $3.15, or 5.2%, to $57.06. The stock fell as low as $55.80.

Trading volume was five times the average for the company that makes the insomnia drug Lunesta and the asthma drug Xopenex.

The stock was hit because Marlborough, Mass.-based Sepracor predicted 2007's earnings per share, excluding items, would be approximately $2.25 a share, or 15 cents below the average estimate. The full-year revenue forecast of $1.46 billion was in line with the consensus of $1.44 billion from analysts polled by Thomson First Call.

Higher expenses and lower earnings guidance for this year were a "surprise," says David Steinberg of Deutsche Bank Securities in a research note to clients. He had been predicting 2007 earnings of $2.45 a share.

Steinberg kept his buy rating. His firm does, or seeks to do, business with companies covered in research reports.

The shock for this year overwhelmed the news for the fourth quarter, in which Sepracor earned $99.1 million, or 85 cents a share, on revenue of $357.2 million. The results included charges of $13.8 million, or 12 cents a share, for stock-based compensation.

Analysts had predicted fourth-quarter earnings of 62 cents a share on revenue of $341.3 million.

If you liked this article you might like

Are Fund Managers Better Than Their Funds?

Are Fund Managers Better Than Their Funds?

Can Regional Brokers Keep Outperforming?

Can Regional Brokers Keep Outperforming?

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

Cosmetic Surgery Stocks Keep Stiff Upper Lip

Cosmetic Surgery Stocks Keep Stiff Upper Lip

For Abbott, Diversity Remains Paramount

For Abbott, Diversity Remains Paramount